Could a common laxative soothe gut inflammation in cystic fibrosis?
NCT ID NCT04458129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial investigates whether polyethylene glycol (a laxative) can reduce intestinal inflammation in children with cystic fibrosis. The study includes children aged 4 to 17 with cystic fibrosis and pancreatic insufficiency who have elevated fecal calprotectin (a marker of gut inflammation). Participants take polyethylene glycol daily for 3 months, and the main goal is to see if their calprotectin levels drop below a certain threshold, indicating reduced inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
polyethylene glycol (Macrogol 4000)
What this could lead to
If it works, this could offer a simple, non-drug way to manage gut inflammation in children with cystic fibrosis, improving digestive health.
What could go wrong
This is a small, early-phase trial with only 23 participants. The treatment may not reduce inflammation enough, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Bordeaux
Bordeaux, 33000, France